There is a kind of invisible cultural wall between patients such as cancer patients and biomedical scientists like me, but this wall does not have to exist and indeed it is a negative wall as patients, scientists, doctors, agencies, and advocates can achieve far more together than apart. But the wall is surprisingly strong. Last […]
My Cancer: how I became an advocate too Read More »
What is stem cell-derived blood? In 2010 I blogged about the exciting finding that researchers could derive most blood cell types from stem cells. You can read more about that here. Here also is a video of Micky Bhatia discussing the findings: Mick Bhatia on turning skin cells into blood. Stem cell-derived blood Now comes a
Is stem cell-derived blood on the horizon? Read More »
Yesterday I wrote about how difficult it is to tell different cell lines apart, including normal stem cells and cancer stem cells, especially since some accumulate accumulate oncogenic mutations that may make them seem more similar. A new paper is coming out that makes this case on a genomic level. Tomorrow’s Cell Stem Cell edition
Devil in the details: small oncogenic lesions in iPS cells & ESC Read More »
What makes stem cells different? The stem cell field is faced with a dilemma as stem cells and some non-stem cells are sometimes too similar to tell apart. Even worse, stem cells and cancer cells are especially similar. If one focuses specifically on cancer stem cells (aka tumor initiating cells), the similarity between cancer stem
What makes stem cells different? Read More »
In this post I give my most interesting predictions about events in the stem cell field in 2011. Update: I’ve continuing doing predictions every year all the way through 2020 and intend to continue. See my 2012-2020 predictions here. Appeals court rules in favor of federally funded hESC research. This is more of a hope
Predictions for Stem Cells in 2011 Read More »
Advanced Cell Technology (ACT) announced that the FDA has approved their second human ES cell-based clinical trial, a combined Phase I/II, for the treatment of blindness. Advanced Cell Technology As a result, soon ACT will have two active, human ES cell-based clinical trials, both using the same human ES cell-based drug. The aim of the
FDA approves Advanced Cell Technology second stem cell trial for blindness Read More »
Cancer patients and their doctors face daunting challenges at the time of diagnosis. Many crucial questions either cannot be answered or rely upon relatively low-tech methods whose accuracy is far from ideal. For example, how aggressive is this tumor? Has it already spread? After diagnosis and initial treatment, it is critical to monitor patients for
One in a billion: finding stray cancer stem cells Read More »
The DC Appeals Court hears oral arguments today in the case over whether the federal government can legally fund embryonic stem cell (ESC) research. At stake are dozens of research projects that could provide treatments or cures for millions of Americans. Reportedly, an amicus brief to the court has been filed on behalf of Associate
Sheng Ding’s lab reports today in Cell Stem Cell (you can read it here) that they have replaced all genetic factors in a new iPS cell reprogramming method except Oct4. The other factors were replaced by chemical compounds. Thus, we continue a major transition in the iPS cell field away from genes and toward chemicals.
From genes to chemicals: iPS cell field, reprogramming in transition Read More »
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to
Challenges translating stem cell treatments to patients Read More »